Understand how we got here — and how to move forward.


October 3, 2022

Around the nation: WHO releases guidelines for mental health at work

Daily Briefing

    The World Health Organization (WHO) released a report that provides guidelines for mental health in the workplace, in today's bite-sized hospital and health industry news from California, the District of Columbia, and Tennessee.

    • California: Attorney General Rob Bonta last month announced that California will soon become the only state to have a government office dedicated to preventing gun violence. The Office of Gun Violence Prevention will partner with multiple agencies to address the growing issue of gun violence in California. Along with federal, state, and local partners, the office will encourage research and data collection, support the Justice Department's efforts to reduce gun violence, and assess a wide range of measures to reduce gun violence. "This is a moment of crisis in America," Bonta said. "This crisis demands more than thoughts and prayers ... it demands action now, and we are delivering." (Vainshtein, San Francisco Chronicle, 9/21)
    • District of Columbia: WHO released a report that provides guidelines for mental health in the workplace. According to WHO, the report was created to provide "evidence-based recommendations to promote mental health, prevent mental health conditions, and enable people living with mental health conditions to participate and thrive in work." The agency includes recommendations for interventions at the organizational level, training managers, training workers, and individual interventions. For each recommendation, WHO explained the evidence, rationale, and process from evidence to decision. The report also provides recommendations for employees returning to work after a mental health-related absence, recommendations for finding employment for individuals with mental health conditions, and information about screening programs. (Hou, "Changing America," The Hill, 9/29)
    • Tennessee: FDA last month approved Daxxify, a new drug from Revance Therapeutics that reduces the appearance of facial wrinkles for around six months—a move that brings competition to a market that has been dominated by Botox for decades. According to Revance Therapeutics, Daxxify's effects last longer than existing products on the market. Balaji Prasad, who focuses on specialty pharmaceuticals as a Barclays Investment Bank analyst, said that the development of Daxxify marks the most significant advance in the $3 billion facial injection drug market since Botox was released. "Users do not have to go once every three months," Prasad said. "In a world where time is of the essence, having a product with a long duration factor is extremely useful." (Jewett, New York Times, 9/8)

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.